Corona Remedies Ltd 31 Oct 2026 12:00 AM
Corona Remedies Ltd consolidated sales up 4.44% on year in Q3FY2026,
Corona Remedies Ltd share price declined by 3.12% to Rs 2146.05. The Company`s net profit inched up 0.33% to Rs 60.31 crore, while revenue from operations improved marginally 4.44% to Rs 441.17 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, easing 4.48%. It has marginally improved by 6.57% over last one week and crept higher by 1.39% in last one month while the market capitalization of Corona Remedies Ltd has improved by 4.45% and 2.31% in the same period respectively. Profit before tax (PBT) of Corona Remedies Ltd stood at Rs 80.75 crore in Q3 FY26, rallying 15.72% year-on-year, and gaining 0.49% quarter-on-quarter. EBITDA came in at Rs 93 crore, expanding by 22.66% YoY and rising 3.88% sequentially. Total expenses posted a minor rise of 5.18% to Rs 360.28 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 35.01 crore, growing marginally by 7.23% YoY, while employee benefits expense was at Rs 124.24 crore, ticking higher by 1.76% YoY. For the TTM ended FY26, revenue from operations improved 17.28% to Rs 1403.18 crore, while net profit soared by 23.88% to Rs 185.12 crore, compared to previous TTM. EBITDA surged by 23376% to Rs 282.79 crore, and PBT surged 21.10% to Rs 240.42 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 229.48 crore in FY26, as against Rs 190.5 crore in FY25. Corona Remedies Ltd jumped 49.32% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 11.78% during the same period.
Corona Remedies Ltd 16 Oct 2026 12:00 AM
Corona Remedies to review financial results at board meeting on October 30, 2026,
CORONA Remedies Limited will hold a board meeting on Friday, October 30, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the second quarter and half year ended September 30, 2026, and other business matters. The trading window for dealing in the company`s securities will remain closed until Sunday, November 01, 2026, as previously communicated on September 28, 2026.
Corona Remedies Ltd 05 Oct 2026 12:00 AM
Corona Remedies confirms Regulation 74(5) non-applicability through Bigshare Services,
Corona Remedies Limited informed the BSE Limited and National Stock Exchange of India that Bigshare Services Private Limited, the company`s Registrar to Issue and Share Transfer Agent, has confirmed the non-applicability of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as all shares are held in demat form and no requests for rematerialization or dematerialization were received.
Corona Remedies Ltd 28 Sep 2026 12:00 AM
Corona Remedies closes trading window ahead of second quarter financial results,
CORONA Remedies Limited informed the BSE Limited and National Stock Exchange of India Limited that the trading window for dealing in the company`s securities will be closed from October 01, 2026, until 48 hours after the declaration of the unaudited financial results for the second quarter and half year ending September 30, 2026, in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.
Corona Remedies Ltd 01 Aug 2026 12:00 AM
Corona Remedies consolidated net profit rises 30.11% in the June 2026 quarter,
Net profit of Corona Remedies rose 30.11% to Rs 60.11 crore in the quarter ended June 2026 as against Rs 46.20 crore during the previous quarter ended June 2025. Sales rose 21.90% to Rs 422.43 crore in the quarter ended June 2026 as against Rs 346.54 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales422.43346.54 22 OPM %22.0520.08 - PBDT93.6069.61 34 PBT80.3660.69 32 NP60.1146.20 30 Powered by Capital Market - Live News
Subscribe for our
newsletter
Open Account Now